The invention relates to medicine, particularly to the treatment of patients wih malignant tumours, using a combination of cytostatic therapy and biotherapy. A method of treating malignant haematological diseases or melanoma in a subject by applying cytostatics impacting mainly DNA in combination with N-acetyl-D-glucosaminyl-β-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) according to the following treatment regimen for subjects: intravenous administration of from 1/4 to 1/2 of the standard therapeutic dose of a cytostatic established for this type of subjects then, in an hour, following the administration of the cytostatic, the first administration of N-acetyl-D-glucosaminyl-β-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) in an effective amount set forth for these subjects repeated administrations of GMDP-A in an effective amount set forth for the selected subjects, once a day within 4-20 days. The technical result of the proposed invention increasing the efficiency of treatment of malignant haematological diseases or melanoma involves a synergistic effect achieved through the combined impact of a cytostatic selected from the group of cyclophosphan, cisplatin, gemcitabine and an immune modifier thereof, which makes it possible to reduce the therapeutic dose of highly toxic cytostatics selected from the group of cyclophosphan, cisplatin, gemcitabine without reducing their antitumour efficacy.Изобретение относится к медицине, конкретно к лечению больных со злокачественными опухолями сочетанием цитостатической и биотерапии. Способ терапии злокачественных гематологических заболеваний или меланомы у субъекта путем применения цитостатиков и воздействующих преимущественно на ДНК в комбинации с N-ацетил-D-глюкозаминил-β-(1-4)-N-ацетилмурамил-L-аланил-D-глутаминовой кислотой (ГМДП-А) по следующей схеме лечения субъектов: введение внутривенно от 1/4 до 1/2 стандартной терапевтической дозы принятой для данного вида субъектов цитостатика затем через час пос
